<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229838</url>
  </required_header>
  <id_info>
    <org_study_id>1178.1</org_study_id>
    <nct_id>NCT02229838</nct_id>
  </id_info>
  <brief_title>Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food</brief_title>
  <official_title>Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of 0.25 mg, 0.75 mg, 2 mg, 6 mg, and 10 mg BIBB 1464 MS (Tablet) in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food of the Dose of 0.75 mg or 2 mg or 6 mg (Two-stage Trial Design With Randomised Double Blind Placebo Controlled Rising Dose Phase and Subsequent Randomised, Open Parallel Group Phase)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Safety, pharmacodynamics and pharmacokinetics of 0.25, 0.75, 2.0, 6.0, and 10 mg BIBB 1464&#xD;
      p.o once daily in a rising dose group-comparison (placebo controlled, double blind,&#xD;
      randomized per dose level).&#xD;
&#xD;
      Relative Bioavailability of 0.75 mg or 2 mg or 6 mg ( tablet vs. solution, intraindividual&#xD;
      comparison), preliminary assessment of food effects (interindividual comparison)&#xD;
&#xD;
      Two-stage Trial Design With Randomised Double Blind Placebo Controlled Rising Dose Phase and&#xD;
      Subsequent Randomised, Open Parallel Group Phase).&#xD;
&#xD;
      MS (Tablet) in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative&#xD;
      Bioavailability and Effect of Food of the Dose of 0.75 mg or 2 mg or 6 mg (Two-stage Trial&#xD;
      Design With Randomised Double Blind Placebo Controlled Rising Dose Phase and Subsequent&#xD;
      Randomised, Open Parallel Group Phase).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <primary_completion_date type="Actual">September 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum drug plasma concentration (Cmax)</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach the maximum concentration of the analyte in plasma (tmax)</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total area under the plasma drug concentration-time curve (AUC)</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total plasma clearance divided by the systemic availability factor (CL/f)</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose normalized AUC0-38h ( NAUC0-38h)</measure>
    <time_frame>Up to 38 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time, total (MRTtot)</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 72 hours after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinical significant findings in vital signs</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinical significant findings in electrocardiogram (ECG)</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinical significant findings in physical examination</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator assessed tolerability on a 4 point scale</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monoepoxysqualene (MES) plasma concentration</measure>
    <time_frame>Up to 38 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of drug excreted in urine</measure>
    <time_frame>Up to 38 h after drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBB 1464 MS single rising dose fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBB 1464 MS tablet fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBB 1464 MS solution fasted</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBB 1464 MS placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBB 1464 MS tablet</intervention_name>
    <arm_group_label>BIBB 1464 MS single rising dose fed</arm_group_label>
    <arm_group_label>BIBB 1464 MS tablet fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBB 1464 MS solution</intervention_name>
    <arm_group_label>BIBB 1464 MS solution fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBB 1464 MS placebo</intervention_name>
    <arm_group_label>BIBB 1464 MS placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard dinner</intervention_name>
    <arm_group_label>BIBB 1464 MS single rising dose fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects as determined by results of screening&#xD;
&#xD;
          -  Signed written informed consent in accordance with good clinical practice (GCP) and&#xD;
             local legislation&#xD;
&#xD;
          -  Age &gt; 18 and &lt; 55 years&#xD;
&#xD;
          -  Broca &gt; - 20% and &lt; + 20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any findings of the medical examination (including blood pressure, pulse rate and ECG)&#xD;
             deviating from normal and of clinical relevance.&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal (including thyroid) disorder&#xD;
&#xD;
          -  Surgery of the gastro-intestinal tract (except appendectomy)&#xD;
&#xD;
          -  Disease of the central nervous system (such as epilepsy) or psychiatric disorders&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant&#xD;
             to the trial as judged by the investigator&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt; 24 hours) (&lt;= 1 month prior to administration&#xD;
             or during the trial)&#xD;
&#xD;
          -  Use of any drugs which might influence the result of the trial (&lt;= 10 days prior to&#xD;
             administration or during the trial)&#xD;
&#xD;
          -  Participation in another trial with an investigational drug (&lt;= 2 month prior to&#xD;
             administration or during the trial)&#xD;
&#xD;
          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt;3 pipes/day)&#xD;
&#xD;
          -  Inability to refrain from smoking during the period of the study&#xD;
&#xD;
          -  Known alcohol (&gt;60 g/day) or drug abuse&#xD;
&#xD;
          -  Blood donation (&lt;=1 month prior to administration)&#xD;
&#xD;
          -  Excessive physical activities (&lt;5 days prior to administration)&#xD;
&#xD;
          -  Any laboratory value outside the normal range of clinical relevance&#xD;
&#xD;
          -  History of hemorrhagic diatheses&#xD;
&#xD;
          -  History of gastro-intestinal ulcer, perforation or bleeding&#xD;
&#xD;
          -  History of bronchial asthma&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2014</study_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

